EdiGene Funding: $129M Raised, Series B (2021)

EdiGene funding overview

EdiGene is based in Cambridge. EdiGene has raised $129M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series B announced in April 2021. The round record for EdiGene runs through 2021; nothing later has been disclosed. Investors on record include Loyal Valley Capital, BioTrack Capital, Sherpa Healthcare Partners, IDG Capital, Lilly Asia Venture, 3H Health Investment and 4 others. 10 distinct backers are named across the disclosed rounds.

EdiGene at a glance

Total raised: $129M
Latest round: Series B
Latest round date: April 2021
Headquarters: Cambridge
Notable investors: Loyal Valley Capital, BioTrack Capital, Sherpa Healthcare Partners, IDG Capital, Lilly Asia Venture, 3H Health Investment, Huagai Capital, Sequoia Capital China

Frequently asked about EdiGene funding

How much has EdiGene raised?: EdiGene has raised $129M in total disclosed funding across the rounds on record.
Who has invested in EdiGene?: Loyal Valley Capital, BioTrack Capital, Sherpa Healthcare Partners, IDG Capital, Lilly Asia Venture, 3H Health Investment are named among the investors backing EdiGene.
What was the latest EdiGene funding round?: The most recent disclosed round is a Series B, announced in April 2021.
Where is EdiGene based?: EdiGene is based in Cambridge.
When did EdiGene last raise?: The last disclosed EdiGene round closed in April 2021 at Series B.

Every EdiGene figure above comes from filings and announced rounds in the StartupFundraising company database and is revised as new rounds are recorded. The lists below compare companies in Cambridge at a similar stage.

EdiGene Funding: $129M Raised, Series B (2021)

EdiGene funding overview

EdiGene at a glance

Frequently asked about EdiGene funding

Companies related to EdiGene (33)

Browse related funding lists (8)